Published in Business

Alcon officially acquires Aerie

This is editorially independent content
1 min read

Remind me again what this means. 

Alcon’s ophthalmic commercial product portfolio now includes Rocklatan (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% and Rhopressa (netarsudil ophthalmic solution) 0.02%. (via)

What’s in the pipeline?

Alcon has acquired several clinical and preclinical candidates for retinal and ocular surface diseases in the pipeline, with the most notable being AR-15512, a phase 3 product candidate for dry eye disease.

Why is this significant?

The company now has a major hold in the ophthalmic pharmaceutical industry, having also acquired the exclusive U.S. commercialization rights for Simbrinza (brinzolamide/brimonidine tartrate ophthalmic suspension) 1%/0.2% from Novartis in April 2021 and—more recently— Eysuvis (loteprednol etabonate) and Inveltys (loteprednol etabonate ophthalmic suspension) 1% from Kala Pharmaceuticals in May 2022. 

Any product changes I should know about?

For now, all order processes will remain the same for products formerly under Aerie, along with payment terms and conditions. (via)

Where should I buy Rocklatan and Rhopressa samples?

HCP samples will be available via the Alcon sample portal beginning December 1.